Come join me, ⁦Mazen Noureddin, MD, MHSc⁩ and Dr. Meena Bansal for this interactive program. Rezdiffra is here, Semaglutide may follow soon! Learn everything you need to start meds for #MASLD ⁦Madrigal Pharmaceuticals⁩ ⁦Novo Nordisk US Medical⁩ ⁦Arizona Liver Health⁩ eventbrite.com/e/entering-a-n…

The results of the interim analysis of Survodutide for MASH w fibrosis were presented today at Digestive Disease Week . 🔑 findings: 1. Up to 90% decreased liver fat by > 30%. 2. Great reduction in ALT/ AST. Great reduction in ELF. The future is bright Mazen Noureddin, MD, MHSc VCU Stravitz-Sanyal Institute for Liver Disease Ramy Younes, MD, PhD g

Very excited to announce the ALH/ ACT Learning Academy to work with our pharma partners, providers, and diagnostic companies to educate on everything liver disease and beyond. Anita Kohli Arizona Liver Health Mazen Noureddin, MD, MHSc SurfingMASH Madrigal Pharmaceuticals Boehringer Ingelheim Novo Nordisk US Medical

Check out this comprehensive review on GLP1/GIP/GCG agonists. Thanks @Elfeki83 for leading:) Arizona Liver Health Mazen Noureddin, MD, MHSc Aleksander Krag Rohit Kohli (He/Him) Boehringer Ingelheim Novo Nordisk Merck Altimmune, Inc. Sonal Kumar, MD MPH Robert G. Gish Anita Kohli

Looking forward to presenting our paper on the long term outcomes of bariatric surgery in pts w MASH Cirrhosis on behalf of the SPECCIAL investigators. Ali Aminian Mazen Noureddin, MD, MHSc Elliot Tapper VCU Stravitz-Sanyal Institute for Liver Disease Rohit Loomba Global Liver Institute Philip Schauer, MD Dr. John Kirwan Arizona Liver Health

Remembering our dear friend and role model Dr. Stephen Harrison at #EASL2024. He made a big fat dent on fatty liver research. EASL Education AASLD Mazen Noureddin, MD, MHSc Pinnacle Clinical Research Arizona Liver Health Raj VuppaLanchi Rashmee Patil MD Michael Charlton MD, FRCP Maru Rinella MD Madrigal Pharmaceuticals

Survodutide histology data is out. Great MASH resolution AND Fibrosis regression. Boehringer Ingelheim VCU Stravitz-Sanyal Institute for Liver Disease Mazen Noureddin, MD, MHSc Ramy Younes, MD, PhD Arizona Liver Health Juan Pablo (JP) Arab, MD  Rohit Loomba Rohit Kohli (He/Him) Anita Kohli Raj VuppaLanchi Elliot Tapper FattyLiverAlliance AASLD President EASLnews

Very excited to be part of this webinar. Although PFICs are thought of as pediatric diseases, they affect a significant percentage of adults with unexplained chronic liver diseases! Mirum Pharmaceuticals IpsenUS Travere Therapeutics GSK Arizona Liver Health Pierre Gholam Northeast Ohio Liver Alliance Echosens

I had the pleasure of working with Medscape Education on a recent activity designed to help you learn more about treating metabolic dysfunction-associated steatohepatiti. Don’tforget to share your thoughts with me after taking it. Arizona Liver Health medscape.org/viewarticle/10…

Excited to present at this meeting with Northeast Ohio Liver Alliance Pierre Gholam PFICNETWORK . Join us by registering at liveralliance.org Mazen Noureddin, MD, MHSc Ipsen Mirum U.S. Travere Therapeutics Global Liver Institute Arizona Liver Health Anita Kohli

Our new data showing the impact of MASLD on the US adult population. Advanced fibrosis in 8% of American adults and cirrhosis in 1.1%. Big implications for healthcare. Echosens Madrigal Pharmaceuticals Novo Nordisk US Medical Eric Topol Fibronostics akerotx Mazen Noureddin, MD, MHSc bmcgastroenterol.biomedcentral.com/counter/pdf/10…

Happy to share our PUVENAFLD trial. Combo DHA + Vit E did NOT improve MASLD. Important info. Let’s focus on developing drugs that work for liver fibrosis ⁦Mazen Noureddin, MD, MHSc ⁦Naga Chalasani⁩ . Alimentary Pharmacology & Therapeutics onlinelibrary.wiley.com/doi/10.1111/ap…

So excited for our largest expansion at Arizona Liver Health so far:) 30,000 sq ft dedicated to cutting edge clinical research. Our focus is on hepatic and renal impairment trials:) Mazen Noureddin, MD, MHSc Sagimet Biosciences IpsenUS Boehringer Ingelheim Regeneron Pfizer Inc. akerotx AASLD President

Arguably one of the most important figures in Hepatology in 2024. How to select appropriate patients for MASH Rx. Nothing is perfect but action is needed and liver biopsy is ☠️ Mazen Noureddin, MD, MHSc EASL Education Aleksander Krag AASLD President Madrigal Pharmaceuticals Novo Nordisk US Medical Echosens

A must attend virtual session. Can we do it all with one drug that leads to MASH resolution/ fibrosis regression/ weight loss/ better outcomes? Mazen Noureddin, MD, MHSc Boehringer Ingelheim Merck Altimmune, Inc. Juan Pablo (JP) Arab, MD  Pinnacle Clinical Research Anita Kohli

Earn CME while having fun with this interactive program. Pierre Gholam GHAPP Maru Rinella MD Mazen Noureddin, MD, MHSc Sonal Kumar, MD MPH Raj VuppaLanchi EASLnews AASLD Arizona Liver Health Michelle Jones Mohamed Elfeki Madrigal Pharmaceuticals Novo Nordisk Inventiva Pharma akerotx Echosens North America

Very exciting news for Arizona Liver Health . Hope to become the place for hepatic impairment trials and research imaging:) Mazen Noureddin, MD, MHSc Amreen Dinani Alina Allen Madrigal Pharmaceuticals akerotx ProSciento, Inc. Fortrea Boehringer Ingelheim Eli Lilly and Company VCU Stravitz-Sanyal Institute for Liver Disease Rohit Loomba

Thank you Consultant360 for putting this interview together with ⁦Mazen Noureddin, MD, MHSc⁩ and ⁦Amreen Dinani⁩ to discuss this 🔥 topic! Resmetirom and NITs! ⁦Madrigal Pharmaceuticals⁩ ⁦Echosens⁩ ⁦Resoundant⁩ ⁦Arizona Liver Health⁩ consultant360.com/videos/initiat…

Big thank you to FattyLiverAlliance for doing this virtual tour of our brand new phase 1 unit. Our team is ready to do cutting edge trials including hepatic impairment/ Renal impairment/ first in human/ DDI/ food impact/ SAD/ MAD/ and mechanistic studies. Elliot Tapper Mazen Noureddin, MD, MHSc

Best Buy Interventions in MASH. A new concept that can make a big difference for our patients by targeting upstream events. Thank you Jeffrey V. Lazarus for leading this. Madrigal Pharmaceuticals Alina Allen Novo Nordisk Echosens American Liver Foundation National #livertwitter thelancet.com/journals/langa…